|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we provide an overview of the role of GLP-1 and GLP-2 in lipid homeostasis and metabolic disease including NAFLD and NASH.
|
30578967 |
2019 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The ketotic cows displayed hepatic lipid metabolic disorder and high blood concentration of glucagon.
|
30478902 |
2019 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
There is very solid evidence that glucagon is an important hormone in human and mammalian metabolism, but its precise physiological role in glucose and lipid metabolism and in metabolic disease has been difficult to establish, not least because of these difficulties.
|
31671667 |
2019 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Gestational diabetes mellitus (GDM) is the most common metabolic disorder in pregnancy and is characterized by insulin resistance and decreased circulating glucagon-like peptide-1 (GLP-1).
|
31164969 |
2019 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Gender Differences in the Pharmacological Actions of Pegylated Glucagon-Like Peptide-1 on Endothelial Progenitor Cells and Angiogenic Precursor Cells in a Combination of Metabolic Disorders and Lung Emphysema.
|
31671663 |
2019 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, GLP-1 receptors (GLP-1-R) have emerged as a promising target in the treatment of metabolic disorders.
|
31337027 |
2019 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The present results also suggested that the effects of GLP-1 on endocrine and metabolic diseases are possibly mediated by modulation of signaling pathways, and provide a basis for pharmacologic targeting of macrophage activation and an insight into the molecular mechanisms involved in the progression of metabolic diseases.
|
30988739 |
2019 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The development and utility of balanced, unimolecular multireceptor agonists provide both a useful tool for querying the actions of incretins and glucagon during metabolic disease and a unique drug class to treat type 2 diabetes with unprecedented efficacy.
|
29905825 |
2018 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical and pre-clinical studies, discussed in this review, suggest that modulation of GLP1/miRNAs pathway may be a useful and innovative therapeutic strategy for prevention and treatment of metabolic disorders, such as diabetes mellitus and liver steatosis.
|
30581418 |
2018 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This heretofore-unappreciated aspect of glucagon biology has implications for the use of GCGR agonism in the therapy of metabolic disorders.
|
29925501 |
2018 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we will focus on new conceptual aspects of glucagon biology and how this may led to new diagnostics and treatment of metabolic diseases.
|
29412830 |
2018 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
New evidence is shedding more light over the complex physiology of GLP-1 in health and metabolic diseases.
|
30364192 |
2018 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated the mechanism of hepatosteatosis induced by anti-CD3 antibody and the effects of glucagon-like peptide-1 (GLP-1) receptor agonist that was recently shown to affect immune function in metabolic disorders.
|
28684145 |
2017 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
(2017) report a proof-of-concept study using genetically engineered skin transplants that produce the incretin GLP-1 to prevent diet-induced obesity, suggesting a powerful approach for treating metabolic disorders.
|
28777938 |
2017 |
|
Metabolic Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These findings have implications for conditions characterized by elevated circulating levels of GLP-2 such as after bariatric surgery and the development and use of agents that promote Tgr5 activation, L cell secretion, or GLP-2R agonism for the treatment of metabolic disease.
|
28580281 |
2017 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings link the liver, insulin/glucagon, and lipid metabolism together, which could implicate a role of ANGPTL4 in metabolic diseases.
|
29031727 |
2017 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This review summarizes the extensive historical record and the more recent provocative direction that integrates the prominent role of glucagon in glucose elevation with its under-acknowledged effects on lipids, body weight, and vascular health that have implications for the pathophysiology of metabolic diseases, and the emergence of precision medicines to treat metabolic diseases.
|
28275047 |
2017 |
|
Metabolic Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In this Viewpoint article, Tim Rink and colleagues propose that amylin is an endocrine partner to insulin and glucagon; deficiency or excess of amylin may therefore contribute to important metabolic diseases.
|
8516954 |
1993 |